entx

FINANCIAL REPORT

For the half-year ended 30 June 2025

Table of contents

Page

About this Report

This report has been prepared for entX stakeholders in line with statutory and regulatory obligations. It summarises the Group's operations, performance and financial position as at and for the half year ended 30 June 2025.

All references to entX, the Group, the Company, we, us, and our, refer to entX Limited (ABN 31 164 573 728) and its subsidiaries. All dollar figures are in Australian currency unless otherwise stated. All references to half year refer to the six-month period ending 30 June 2025.

This report should be read in conjunction with the Group's Annual Report for the year ended 31 December 2024.

Directors' Report

Your Directors present this report for the half year ended 30 June 2025.

Directors

The Directors of entX during the half year and until the date of this report are as follows:

- Anthony Kiernan AM (Non-Executive Chairman)
- Bryn Jones (Managing Director)
- Tim Goyder (Non-Executive Director)
- Tim Wise (Non-Executive Director)
- Lucy Gauvin (Non-Executive Director)

Principal activities

entX, through its nuclear science and engineering capabilities, develops scalable technologies for use in the space, defence, and healthcare sectors.

From revolutionary power systems like GenX and RHU to producing pre-cursors for life saving medical treatments, we aim to deliver sustainable solutions that transform industries and create value for shareholders.

These developments are underpinned by several platform technologies and core capabilities that enable the team to operate in areas that have traditionally been encumbered with high barriers to entry.

This key value proposition provides a unique pathway to ultimately unlock commercial opportunities to meet a growing demand globally for resources and sustainable energy supplies.

entX has two distinct commercialisation focus areas:

- ➢ the development of radiation power systems for the Space and Defence and Security sectors.
- ➢ the production of robust medical isotope supply chains to service the radiopharmaceutical industry.

entX prioritises its projects based on their ability to:

- ➢ provide near-term return on investment through cash generation.
- ➢ leverage entX's expertise to secure large and sustainable markets for its products.



Image 1: Photograph of RHU prototype being integrated into the flight demonstration payload.

Financial Review

At 30 June 2025, the Group had net assets of $10,134,259 (31 December 2024: $7,282,611) and a total cash at bank and short term cash deposits of $11,371,558 (31 December 2024: $6,572,679).

The Group reported a net loss for the period of $2,788,634 (30 June 2024: $1,698,224). The increased loss compared to the prior half-year period is primarily as a result of a $1,132,792 increase in direct expenditure on progression of technology research activities (including allocation of direct personnel costs). The expenditure increase reflects both an increase in staff numbers as well as an increase in activities during the reporting period.

During the reporting period the Group's net cash position (which includes short term cash deposits) increased by $4,798,879 from $6,572,679 (1 January 2025) to $11,371,558 (30 June 2025) and the Group has no corporate debt.

Key cash inflows during the reporting period were:

- Funding associated with the issue of new shares in the Company of $5,621,588 (before costs) (30 June 2024: $74,000).
- Grant and other government income of $2,830,303 (30 June 2024: $2,288,292).
- Research and Development tax incentive receipt of $1,146,670 in respect of the claim for the year ended 31 December 2024 (30 June 2024: Nil).
- Proceeds from the sale of the Group's coastal property in Elliston, South Australia of $621,000 (before costs) (30 June 2024: Nil).
- Interest receipts, Urtek LLC management fees and other corporate office rental related inflows of $76,965 (30 June 2024: $55,717).

Key cash outflows during the reporting period were:

- Payments to suppliers and employees of $4,505,790 (30 June 2024: $3,100,687).
- Payments for intellectual property assets and plant and equipment of $566,414 (30 June 2024: $373,114)

Changes in Equity

The following changes in equity took place during the half year ended 30 June 2025:

Shares

The number of fully paid ordinary shares (**Shares**) on issue increased from 177,861,427 (1 January 2025) to 196,800,058 (30 June 2025), following the issue of a total of 18,938,631 new Shares to sophisticated and professional investors at an issue price of $0.30 per Share, raising $5,681,589 (before costs).

Unlisted Options

The number of unlisted options to subscribe for Shares (**Options**) on issue increased from 2,000,000 (1 January 2025) to 6,500,000 (30 June 2025), following the issue of 4,500,000 Options, with each Option exercisable at $0.435 each and expiring on or before 31 May 2028.

Refer Note 18 for further details regarding Options on issue and associated movements during the reporting period.

Dividends

No dividends were paid, recommended or declared during the current or previous reporting period.

Significant changes to the state of affairs

The Directors are not aware of any significant changes in the state of affairs of the Group occurring during the half-year ended 30 June 2025, other than as disclosed in this half year report.

Review of Operations

Overview

entX continues to advance its Space & Defence, Medical Isotopes, and Future Technologies divisions through strong collaborative partnerships and strategic initiatives. With IsoMedica progressing towards commercial isotope production, GenX technologies progressing towards commercialisation, and new pathways for uranium recovery from phosphates under evaluation, the Group is well-positioned to deliver sustainable growth and long-term market leadership across its core sectors.

Medical Isotopes: Scaling Production and Commercialisation

IsoMedica, entX's medical isotope division, continues its transition from laboratory development to early-stage commercial production, laying the foundations for long-term growth in the global radiopharmaceutical market.

Key operational achievements:

- **Commercial facility:** entX has received key permits for Australia's first commercial radioisotope production facility, with major construction contracts under negotiation. The facility will enable the extraction and processing of precursors to medical isotopes, including Lutetium-177 and Lead-212, for supply to the healthcare industry, and is targeted to be operational by mid-2026.

- **Isotopic Enrichment:** Pilot facilities for Ytterbium-176 enrichment have been completed and will run throughout 2025, positioning entX to be a critical supplier to the Lutetium-177 supply chain from 2026 onwards subject to securing commercial supply agreements.

- **Commercial focus ahead:** These projects are progressing on schedule, with the Company expecting to be in a position to supply commercial products within the next 12 months from the Advanced Radioisotope Production facility in Adelaide. Supply agreements are being advanced both in Australia and internationally.

On successful completion of these projects, entX will be at the forefront of isotope supply for nuclear medicine with the capability to provide reliable and scalable production to enable next-generation cancer therapies.

Image 2: entX employee conducting test work at the Company's laboratory facilities in Adelaide, South Australia.

Space & Defence: Advancing Radioisotope Power System Solutions

entX continues to advance the development of its radioisotope power and heating technologies for extreme environments. Our GenX Power Systems and Radioisotope Heating Units (RHUs) are undergoing rigorous testing and validation, positioning the Company for commercial deployment in autonomous defence and lunar missions.

Key operational progress:

- **Grant and strategic partnerships**: During the reporting period, entX secured a total of $1.2 million in grant funding, comprising a $1 million award from the Australian Space Agency's Moon to Mars Initiative and a $0.2 million award from the South Australian Government's Space Collaboration and Innovation Fund. These grants support the development and flight heritage of entX's RHU and collaborative feasibility studies with ispace to accelerate lunar-night survival technology solutions using RHUs.
- **GenX production capacity:** Construction is underway on a facility designed to produce 200 GenX units per year. The facility is expected to be completed by the end of 2025, with customer prototypes available in H1 2026.
- **RHU maiden launch:** Safety analysis and permitting are progressing on schedule to enable space flight heritage in H1 2026, paving the way for a lunar mission in 2027.
- **Patents and global expansion:** In June 2025, entX received patents in Australia and Canada for its GenX betavoltaic technology and launched a strategic push into U.S. markets.
- **U.S. footprint**: entX has secured U.S. representation through a prominent firm with deep links to the Department of Defense and major contractors. This has already generated early opportunities within a USD 4 billion appropriations budget for autonomous technologies.

With government and private sector interest in space and defence technologies at an all-time high, entX is well-positioned to secure long-term contracts and commercialisation opportunities in these rapidly evolving industries.

Image 3: Rendered design concept of a GenX Unit.



Image 4: Rendered design of the RHU, shown inside corresponding payload mounting interface

Image 5: This image of a spacecraft orbiting Earth is not an asset of the Company and is used solely for illustrative purposes.

Future Technologies: Developing Energy Solutions

The entX team continues to monitor and identify trends and opportunities in sector and technology development and conceptualises or acquires new technology opportunities for rapid testing and evaluation in order to exploit identified trends and opportunities.

PhosEnergy strategic evaluation continues: entX and Cameco are exploring commercial pathways for the patented PhosEnergy uranium-recovery process, amid a tight nuclear fuel market.

Alternative uranium from phosphate technology: Outside of the current work being undertaken by Urtek, LLC, the PhosEnergy Process owner, entX has also developed and laboratory-tested a 100%-owned alternative process for uranium recovery from phosphate streams and is in the process of securing a commercial pilot project with a prospective partner.

Image 6

Image 7



The above images of a mining operation (Image 6) and the Core of a Nuclear Reactor (Image 7) are not assets of the Company and are used solely for illustrative purposes.

Events arising since the end of the reporting period

The following events have occurred since the reporting date:

Issue of Placement Shares

- On 10 July 2025, the Company issued a further 666,667 new Shares pursuant to the Placement to sophisticated and professional investors that was undertaken during the reporting period, raising a further $200,000 (before costs). Placement Shares were issued at $0.30 per Share.

- On 14 August 2025, the Company issued a further 10,500,000 new Shares pursuant to the Placement to sophisticated and professional investors, that was undertaken during the reporting period, raising a further $3,150,000 (before costs). Placement Shares were issued at $0.30 per Share.

There were no further significant events arising after the reporting date.

Auditor's Declaration

The auditor's independence declaration as required under section 307C of the Corporations Act 2001 (Cth) is set out on page 8 and forms part of the director's report for the financial half-year ended 30 June 2025.

This report is signed in accordance with a resolution of the Board of Directors.

Bryn Jones
Managing Director

28 August 2025

Auditor's Independence Declaration

Grant Thornton Audit Pty Ltd
Grant Thornton House
Level 3
170 Frome Street
Adelaide SA 5000
GPO Box 1270
Adelaide SA 5001

T +61 8 8372 6666

Auditor's Independence Declaration

To the Directors of entX Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of entX Limited for the half-year ended 30 June 2025. I declare that, to the best of my knowledge and belief, there have been:

a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and

b no contraventions of any applicable code of professional conduct in relation to the review.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants

J L Humphrey
Partner – Audit & Assurance

Adelaide, 28 August 2025

Consolidated Statement of Profit or Loss and Other Comprehensive Income

(For the half-year ended 30 June 2025)

		CONSOLIDATED GROUP	
	Notes	6 months to 30 June 2025 $	6 months to 30 June 2024 $
Revenue from ordinary activities	4(a)	27,000	24,000
Other income	4(b)	1,791,126	1,897,897
		1,818,126	**1,921,897**
Expenses			
Depreciation and lease amortisation expense		(245,755)	(139,264)
Amortisation of intangibles		(8,704)	(18,295)
Research expenses		(2,612,912)	(1,480,120)
Corporate consulting and business development expenses		(84,489)	(798,674)
Employee benefits expense		(1,054,086)	(1,136,048)
Share based payments expense	18	(259,334)	-
Share based payments expense written back - forfeited options	18	-	217,438
Other expenses		(304,460)	(258,387)
		(4,569,740)	**(3,613,350)**
Loss before financing costs		**(2,751,614)**	**(1,691,453)**
Finance costs		(37,020)	(6,771)
Loss before income tax		**(2,788,634)**	**(1,698,224)**
Income tax benefit		-	-
Loss attributed to members of the parent		**(2,788,634)**	**(1,698,224)**
Other comprehensive income/(loss)			
Items that may be reclassified to profit or loss			
Exchange differences on translation of foreign operations – gain / (loss)		1,229	(3,497)
Other comprehensive loss net of tax		**1,229**	**(3,497)**
Total comprehensive loss attributable to members of the parent		**(2,787,405)**	**(1,701,721)**
Basic and diluted loss per share (cents per share)		(1.55)	(1.15)

The financial statements should be read in conjunction with the accompanying notes.

Consolidated Statement of Financial Position

(As at 30 June 2025)

		CONSOLIDATED GROUP	
	NOTES	30 June 2025 $	31 December 2024 $
ASSETS			
Current assets			
Cash and cash equivalents	7	6,264,289	6,535,068
Term deposits	7	5,107,269	37,611
Trade and other receivables	8	968,581	1,123,599
Contract assets	22	121,384	193,672
Assets classified as held for sale	10	-	629,843
Total current assets		**12,461,523**	**8,519,793**
Non-current assets			
Intangible assets	11	278,430	223,691
Property, plant and equipment	12	1,110,480	468,719
Right to use assets – office and lab facility leases	14	943,723	523,213
Total non-current assets		**2,332,633**	**1,215,623**
TOTAL ASSETS		**14,794,156**	**9,735,416**
LIABILITIES			
Current liabilities			
Trade and other payables	13	1,289,514	876,755
Contract liabilities	22	1,960,872	-
Lease liabilities	14	331,888	246,631
Employee entitlements	17	292,396	923,652
Total current liabilities		**3,874,670**	**2,047,038**
Non-current liabilities			
Lease liabilities	14	674,690	300,559
Employee entitlements	17	110,537	105,208
Total non-current liabilities		**785,227**	**405,767**
TOTAL LIABILITIES		**4,659,897**	**2,452,805**
NET ASSETS		**10,134,259**	**7,282,611**
EQUITY			
Issued capital	15	24,294,389	18,854,670
Other equity	15	-	60,000
Reserves	16	854,019	593,456
Accumulated losses		(15,014,149)	(12,225,515)
TOTAL EQUITY		**10,134,259**	**7,282,611**

The financial statements should be read in conjunction with the accompanying notes.

Consolidated Statement of Changes in Equity

(For the half-year ended 30 June 2025)

30 JUNE 2025	Issued Capital	Other Equity	Foreign currency translation reserve	Share Based Payments Reserve	Accumulated Losses	Total
	$	$	$	$	$	$
Balance as at 1 January 2025	**18,854,670**	**60,000**	**271,295**	**322,161**	**(12,225,515)**	**7,282,611**
Loss for the year	-	-	-	-	(2,788,634)	**(2,788,634)**
Other comprehensive income	-	-	1,229	-	-	**1,229**
Total comprehensive loss	**-**	**-**	**1,229**	**-**	**(2,788,634)**	**(2,787,405)**
Shares issued during the year	5,681,589	(60,000)	-	-	-	**5,621,589**
Transaction costs associated with share issues	(241,870)	-	-	-	-	**(241,870)**
Expense associated with option vesting during the year	-	-	-	259,334	-	**259,334**
Balance as at 30 June 2025	**24,294,389**	**-**	**272,524**	**581,495**	**(15,014,149)**	**10,134,259**

31 DECEMBER 2024	Issued Capital	Other Equity	Foreign currency translation reserve	Share Based Payments Reserve	Accumulated Losses	Total
	$	$	$	$	$	$
Balance as at 1 January 2024	**12,109,042**	**75,000**	**275,990**	**965,705**	**(9,800,762)**	**3,624,975**
Loss for the year	-	-	-	-	(3,173,020)	**(3,173,020)**
Other comprehensive loss	-	-	(4,695)	-	-	**(4,695)**
Total comprehensive loss	**-**	**-**	**(4,695)**	**-**	**(3,173,020)**	**(3,177,715)**
Shares issued during the year	6,802,784	(75,000)	-	-	-	**6,727,784**
Subscriptions received in advance	-	60,000	-	-	-	**60,000**
Transaction costs associated with share issues	(57,156)	-	-	-	-	**(57,156)**
Expense associated with option vesting during the year	-	-	-	322,161	-	**322,161**
Expense writeback associated with options forfeited during the period	-	-	-	(217,438)	-	**(217,438)**
Transfer of exercised share-based payments to retained earnings	-	-	-	(748,267)	748,267	-
Balance as at 31 December 2024	**18,854,670**	**60,000**	**271,295**	**322,161**	**(12,225,515)**	**7,282,611**

The financial statements should be read in conjunction with the accompanying notes.

Consolidated Statement of Cash Flows

(For the half-year ended 30 June 2025)

		Consolidated Group	
		6 months to 30 June 2025	6 months to 30 June 2024
		$	$
Cash flows from operating activities			
Receipts from customers		42,635	45,445
Grant and other Government income received		2,830,303	2,288,292
Research and development tax concession received		1,146,670	-
Interest received		34,330	10,272
Payments to suppliers and employees		(4,505,790)	(3,100,687)
Net cash outflows from operating activities	**21**	**(451,852)**	**(756,678)**
Cash flows from investing activities			
Payments for term deposits, net of redemptions		(5,069,658)	(224)
Payments for property, plant and equipment		(490,791)	(289,826)
Proceeds from the sale of property– Elliston property		621,000	-
Payments for intellectual property assets		(75,623)	(83,288)
Net cash outflows from investing activities		**(5,015,072)**	**(373,338)**
Cash flows from financing activities			
Repayment of lease liabilities	14	(183,574)	(132,835)
Proceeds from issue of shares	15	5,621,588	74,000
Payment for transaction costs	15	(241,869)	(40,053)
Net cash inflows/(outflows) from financing activities		**5,196,145**	**(98,888)**
Net (decrease)/increase in cash and cash equivalents		(270,779)	(1,228,904)
Cash and cash equivalents at beginning of the period		6,535,068	3,250,955
Cash and cash equivalents at the end of the period	**7**	**6,264,289**	**2,022,051**

The financial statements should be read in conjunction with the accompanying notes.

Notes to the Financial Statements

(For the half-year ended 30 June 2025)

NOTE 1 – STATEMENT OF COMPLIANCE

These interim consolidated financial statements are general purpose financial statements prepared in accordance with the requirements of the Corporations Act 2001 (Cth), applicable accounting standards including AASB 134 'Interim Financial Reporting', Accounting Interpretations and other authoritative pronouncements of the Australian Accounting Standards Board ('AASB'). Compliance with AASB 134 ensures compliance with IAS 34 'Interim Financial Reporting'.

This condensed half year report does not include full disclosures of the type normally included in an annual financial report. Therefore, it cannot be expected to provide as full an understanding of the financial performance, financial position and cash flows of the Group as in the full financial report.

It is recommended that this financial report be read in conjunction with the annual financial report for the year ended 31 December 2024.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, except as set out below. For the purpose of preparing the half year report, the Company is a for profit entity.

NOTE 2 – BASIS OF PREPARATION

The interim report has been prepared on a historical cost basis. Cost is based on the fair value of the consideration given in exchange for assets. The functional and presentation currency of entX Limited is Australian dollars. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.

(a) Significant accounting judgements, estimates and assumptions

The preparation of interim financial reports requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates. In preparing this interim report, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the financial report for the year ended 31 December 2024.

NOTE 3 – SEGMENT REPORTING

The Directors have considered the requirements of AASB 8 – Operating Segments and the internal reports that are reviewed by the chief operating decision maker (the Board) in allocating resources and have concluded that at this time there are no separately identifiable segments.

NOTE 4 – REVENUE AND OTHER INCOME

a) Revenue

	6 months to 30 June 2025 $	6 months to 30 June 2024 $
Management fees	27,000	24,000

The Group's revenue comprises management fees charged to Urtek LLC. Refer to Note 9 for details in relation to Urtek LLC and to Note 20 for details in relation to the management services provided to Urtek LLC.

NOTE 4 – REVENUE AND OTHER INCOME.....continued

b) Other income

	6 months to 30 June 2025 $	6 months to 30 June 2024 $
Grant income	840,094	1,283,693
Research and development tax incentive [1]	865,392	582,811
Interest income	69,886	10,272
Other income	15,671	21,121
Foreign exchange gain	83	-
	1,791,126	1,897,897

1 Represents the research and development tax concession amounts comprising:

- $793,722 relating to the claim estimate for HY25, based on technology research and development expenditure for the half year ended 30 June 2025; and
- $71,670 associated with actual FY24 claim receivable at lodgement being higher than the estimated receivable recorded at 31 December 2024.

ACCOUNTING POLICIES

Research and development (R&D) tax concession

The Group is entitled to claim R&D tax incentives in Australia. The R&D tax incentive is calculated using the estimated eligible expenditures multiplied by a 43.5% non-refundable tax offset. It has been established that the conditions of the R&D incentive have been met and that the expected amount of the incentive can be reliably measured. Estimated amounts receivable are recognised as research and development tax concession income.

Government and other Grant Income

Government and other grants are not recognised until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received. Government grants will be recognised as income over the periods necessary to match them with the related costs which they are intended to compensate on the systematic basis. Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs are recognised in profit or loss in the period in which they become receivable.

NOTE 5 – OTHER EXPENSES

	6 months to 30 June 2025 $	6 months to 30 June 2024 $
Compliance	44,014	30,162
Legal, insurance, share registry	62,789	34,913
Travel expenses	49,638	77,427
Office and website expenses	1,285	40,536
Loss of the sale of the Elliston property (land & buildings)	28,439	-
Other expenses	118,295	75,349
	304,460	258,387

NOTE 6 – LOSS PER SHARE

Basic and diluted loss per share

The calculation of basic loss per share for the half year ended 30 June 2025 was based on the loss attributed to ordinary equity holders of the parent of $2,788,634 (2024: Loss of $1,698,224) and a weighted average number of ordinary shares outstanding during the half year ended 30 June 2025 of 179,864,407 (2024: 147,049,627).

Pursuant to AASB133, there are no dilutive securities on issue due to the loss reported for the period.

NOTE 7 – CASH AND CASH EQUIVALENTS

	30 June 2025 $	31 December 2024 $
Cash at bank and on hand	6,264,289	6,535,068
Short term deposits	5,107,269	37,611

Short term deposits have varying terms between 30 and 365 days.

NOTE 8 – TRADE AND OTHER RECEIVABLES

	30 June 2025 $	31 December 2024 $
Trade receivables	4,900	4,864
Research and development tax concession - HY25 claim estimate	793,722	-
Research and development tax concession - FY24 claim [1]	-	1,075,000
Other receivables	169,959	43,735
	968,581	1,123,599

[1] The actual claim receipt for the FY24 research and development claim of $1,146,670 was $71,670 greater than the receivable at 31 December 2024 ($1,075,000). Accordingly, an additional $71,670 has been recorded as 'other Income' in the Statement of Profit or Loss during the reporting period (refer Note 4 b).

NOTE 9 – INVESTMENT IN ASSOCIATES

The Company and Cameco Corporation developed a process for the extraction of uranium from phosphoric acid streams produced in the production of phosphate-based fertilisers, 'the PhosEnergy Process'. Urtek LLC, a USA incorporated company, is the entity in which the research and development is being undertaken. UFP Investments LLC (UFP), a USA incorporated company in which the Company has a legal and beneficial interest of 28.66%, holds the joint investment of 90% in Urtek LLC with Cameco owning the remaining 10% directly.

The beneficial ownership in the PhosEnergy Process held through Urtek LLC is Cameco Corporation 74.21% (2023: 74.21%): PhosEnergy Inc. 25.79% (2023: 25.79%).

The share of the associate's losses for the half year is $8,198 (US$5,370) (31 December 2024: $24,586 (US$15,285)), which has not been recognised as the carrying amount of the Group's equity accounted interest in this associate is $0 (31 December 2024: $0).

NOTE 10 – ASSETS CLASSIFIED AS HELD FOR SALE

	30 June 2025 $	31 December 2024 $
Land and Buildings – at carrying value	-	629,843

On 12 June 2025, the Group completed the sale of its coastal property (comprising of land and buildings) located in Elliston, South Australia. At completion the company received $621,000 (less sale costs). The land and buildings held for sale were previously recognised at their carrying value at 31 December 2024, following an assessment for any impairment indicators at that time.

NOTE 11 – INTANGIBLE ASSETS

	30 June 2025 $	31 December 2024 $
Cost	312,572	249,129
Accumulated amortisation	(34,142)	(25,438)
	278,430	223,691
Reconciliation of intangible assets		
Carrying amount at the beginning of the period	223,691	525,683
Additions	63,443	179,360
Amortisation charges for the period	(8,704)	(39,437)
Impairment expense	-	(441,915)
Carrying amount at the end of the period	278,430	223,691

The capitalised patent costs for CarbonX and GenT were impaired during the year ended 31 December 2024, however, the Group still actively maintains the patents for these technologies, with patent maintenance expenditure being expensed directly to profit or loss.

Following the prior period impairment of the CarbonX and GenT capitalised patents costs, the remaining capitalised Intangible Assets consist of the patent and intellectual property associated with the GenX Betavoltaic device technology.

NOTE 12– PROPERTY, PLANT AND EQUIPMENT

	30 June 2025 $	31 December 2024 $
a) Plant & Equipment		
Cost	1,278,632	576,547
Accumulated depreciation	(168,152)	(107,828)
	1,110,480	468,719
Movements in carrying amount		
Balance at the beginning of the period	468,719	108,101
Additions	702,084	428,671
Depreciation	(60,323)	(68,053)
Balance at the end of the period	1,110,480	468,719
b) Land		
Cost	-	-
Movements in carrying amount		
Balance at the beginning of the period	-	423,958
Transfer to asset held for sale	-	(423,958)
Balance at the end of the period	-	-
c) Buildings		
Cost	-	211,798
Accumulated depreciation	-	(5,913)
Transfer to asset held for sale		(205,885)
	-	-
Movements in carrying amount		
Balance at the beginning of the period	-	210,125
Depreciation	-	(4,240)
Transfer to asset held for sale		(205,885)
Balance at the end of the period	-	-
Total property, plant and equipment	**1,110,480**	**468,719**

NOTE 13 – TRADE AND OTHER PAYABLES

	30 June 2025 $	31 December 2024 $
Trade payables	662,474	262,244
Other payables	627,040	614,511
	1,289,514	876,755

NOTE 14 – RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

	30 June 2025 $	31 December 2024 $
Lease liabilities		
Opening balance	547,190	388,561
Initial recognition of Gawler Place lease renewal	-	400,011
Initial recognition of Greenfields lease	605,942	
Interest during the reporting period	37,020	15,764
Lease payment during the reporting period	(183,574)	(257,146)
Balance at the end of the reporting period	**1,006,578**	**547,190**
Classified as:		
Current	331,888	246,631
Non-current	674,690	300,559
	1,006,578	**547,190**
Right-of-use-asset		
Balance on initial recognition	749,030	756,771
Initial recognition of Gawler Place lease renewal	-	400,011
Initial recognition of Greenfields lease	605,942	-
Write back of Gawler Place lease ended during the period	-	(407,752)
	1,354,972	**749,030**
Accumulated amortisation		
Balance at the beginning of the reporting period	(225,817)	(390,455)
Amortisation during the reporting period	(185,432)	(243,114)
Write back of Gawler Place lease ended during the period	-	407,752
Balance at the end of the reporting period	**(411,249)**	**(225,817)**
Balance at the end of the reporting period	**943,723**	**523,213**

NOTE 15 – ISSUED CAPITAL

The capital structure of the Group consists of issued capital, reserves and accumulated losses. Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new Shares are shown in equity as a deduction, from the proceeds.

	30 June 2025 $	31 December 2024 $
196,800,058 (31 December 2024: 177,861,427) fully paid ordinary shares	24,294,389	18,854,670

Six months to 30 June 2025	Number of shares	30 June 2025 $
Movements in fully paid shares		
Balance as at 1 January 2025	177,861,427	18,854,670
Shares issued – Placement	18,938,631	5,681,589
Transaction costs for issue of shares	-	(241,870)
Balance as at 30 June 2025	**196,800,058**	**24,294,389**

NOTE 16 – RESERVES

a) Share-based payments reserve

The share-based payments reserve is used to recognise the value of equity-settled share-based payment transactions provided to Directors, other Key Management Personnel, staff and consultants.

	30 June 2025 $	31 December 2024 $
Share based payment reserve	581,495	322,161

Movement associated with Options during the period:		
Balance at the beginning of the period	322,161	965,705
Granted – expense associated with vesting during the period	259,334	322,161
Forfeited – write-back associated with forfeited options	-	(217,438)
Exercised	-	(748,267)
Balance at the end of the period	**581,495**	**322,161**

b) Foreign currency translation reserve

The foreign currency translation reserve is used to record the exchange differences arising from the translation of the financial statements of foreign subsidiaries.

	30 June 2025 $	31 December 2024 $
Foreign currency translation reserve	272,524	271,295

NOTE 17 – EMPLOYEE ENTITLEMENTS

	30 June 2025 $	31 December 2024 $
Current		
Annual leave	217,546	192,443
Long service leave	74,850	54,209
Bonuses accrued	-	677,000
	292,396	**923,652**
Non-current		
Long Service Leave	110,537	105,208
	110,537	**105,208**

NOTE 18 – SHARE BASED PAYMENTS

Options – 30 June 2025

The expense recognised during the reporting period is shown in the table below:

	30 June 2025 $	31 December 2024 $
Share options	259,334	104,723
Movement associated with share-based payments during the period:		
Options vested during the period	259,334	322,161
Options forfeited during the period	-	(217,438)
Balance at the end of the period	**259,334**	**104,723**

Share-based payments expense recognised in Profit or Loss as 'Share based payments' during the reporting period, was in relation to:

- Vesting of Options previously issued that were subject to vesting conditions ($69,209); and
- Vesting of Options issued during the reporting period ($190,125).

The number of options and weighted average exercise prices are as follows for the reporting period presented:

	Weighted Average Exercise Price	6 months to 30 June 2025	Weighted Average Exercise Price	6 months to 30 June 2024
Balance at the beginning of the period	$-	2,000,000	$0.085	15,396,001
Issued during the period	$0.435	4,500,000	-	-
Forfeited during the period	-	-	$0.040	(2,925,000)
Balance at the end of the period	$0.301	6,500,000	$0.096	12,471,001
Vested and exercisable at the end of the period	$0.29	2,250,000	$0.096	12,471,001

Weighted average remaining contractual life of Options as at 30 June 2025 is 2.69 years (30 June 2024: 0.50 years).

Options are unlisted and are exercisable into fully paid ordinary shares in the Company on a one for one basis.

NOTE 18 – SHARE BASED PAYMENTS…….continued

Options granted during the reporting period

On 31 May 2025, 4,500,000 Options, in aggregate were issued to directors of the Company ("Director Options").

Non-executive Directors Lucy Gauvin, Timothy Goyder and Timothy Wise ("Participating Directors") were each issued 1,500,000 Director Options following a review of the remuneration structure for non-executive directors.

Director Options have an exercise price of $0.435 each and expiry of 31 May 2028. The options were granted at no cost to the recipient and vest as follows:

- 1/3rd vested on the date issue (31 May 2025); and
- 2/3rd vest 12 months from the date of issue (31 May 2026).

The Board considered it appropriate and in the best interests of the Company and its shareholders to issue Director Options to supplement the modest cash remuneration currently being paid to Directors Lucy Gauvin, Timothy Goyder and Timothy Wise, and to align their interests with those of shareholders.

In resolving to issue Director Options, the Board considered the provisions of Chapter 2E of the Corporations Act 2001 (Cth) (**Corporations Act**) and the requirement to obtain shareholder approval for the provision of related party benefits, unless an exception applies.

It was resolved that the issue of Director Options constitutes "reasonable remuneration" and falls within the exception stipulated by section 211 of the Corporations Act.

The total fair value at the grant date for the 4,500,000 Options was $489,849 and this amount is being expensed to Profit or Loss under 'share based payments expense' over the vesting periods applicable to the options. Accordingly, an amount of $190,125 has been included in the Profit or Loss under 'share based payments expense' for the reporting period.

Details of the Options granted during the reporting period are set out below:

	Other terms	No. of Options	Earliest Vesting Date
Exercisable at $0.435, expiry 31 May 2028.	Vested immediately on issue, subject to Participating Directors continuing to be engaged as a Director of the Company.	1,500,000	31-May-25
Exercisable at $0.435, expiry 31 May 2028.	Vest 12 months after the issue date, subject to Participating Directors continuing to be engaged as a Director of the Company.	3,000,000	31-May-26
		4,500,000	

The fair value of Options issued during the reporting period was calculated by using a Black-Scholes option pricing model and was estimated on the date of the grant using the following assumptions:

	DIRECTOR OPTIONS
Share price at date of grant ($)	0.30
Historic volatility (%)	66.9
Risk free interest rate (%)	3.414
Expected life of Options (days)	1099

Historical volatility has been the basis for determining expected share price volatility as it is assumed that this is indicative of future tender, which may not eventuate.

The life of the Options is based on the historical exercise patterns, which may not eventuate in the future.

Options exercised during the reporting period

No Options were exercised into Shares during the reporting period or as at the date of this report.

Options lapsed/forfeited during the reporting period

No Options were lapsed or forfeited during the reporting period or as at the date of this report.

NOTE 18 – SHARE BASED PAYMENTS…….continued

The following table outlines the details of outstanding Options as at 30 June 2025:

	Other terms	No. of Options	Earliest Vesting Date
Zero Exercise Price Options ("ZEPOs"), having a nil exercise price and expiring on 1 September 2027.	Vested immediately on issue, subject to Anthony Kiernan continuing to be engaged as a Director of the Company.	1,000,000	1-Sept-24
ZEPOs, having a nil exercise price and expiring on 1 September 2027.	Vested 3 months after the issue date, subject to Anthony Kiernan continuing to be engaged as a Director of the Company.	250,000	1-Dec-24
ZEPOs, having a nil exercise price and expiring on 1 September 2027.	Vested 6 months after the issue date, subject to Anthony Kiernan continuing to be engaged as a Director of the Company.	250,000	1-Mar-25
ZEPOs, having a nil exercise price and expiring on 1 September 2027.	Vested 9 months after the issue date, subject to Anthony Kiernan continuing to be engaged as a Director of the Company.	250,000	1-Jun-25
ZEPOs, having a nil exercise price and expiring on 1 September 2027	Vest 12 months after the issue date, subject to Anthony Kiernan continuing to be engaged as a Director of the Company.	250,000	1-Sept-25
Exercisable at $0.435, expiry 31 May 2028.	Vested immediately on issue, subject to Participating Directors continuing to be engaged as a Director of the Company.	1,500,000	31-May-25
Exercisable at $0.435, expiry 31 May 2028.	Vest 12 months after the issue date, subject to Participating Directors continuing to be engaged as a Director of the Company.	3,000,000	31-May-26
		6,500,000	

NOTE 19 – LIST OF SUBSIDIARIES

The consolidated financial statements include the financial statements of entX and its wholly owned subsidiaries listed in the following table:

Name	Country of Incorporation	Tax Domicile	% Equity interest	
			30 June 2025	31 December 2024
Parent Entity				
entX Limited	Australia	Australia	100	100
Subsidiaries				
PhosEnergy Inc.	USA	USA	100	100
IsoMedica Pty Ltd	Australia	Australia	100	100
GenX Energy Pty Ltd	Australia	Australia	100	100
RHU Solutions Pty Ltd	Australia	Australia	100	100
GenS Technologies Pty Ltd	Australia	Australia	100	100
CarbonX Developments Pty Ltd	Australia	Australia	100	100
GenT Developments Pty Ltd	Australia	Australia	100	100
HPEL Developments Pty Ltd	Australia	Australia	100	100
LCH2 Pty Ltd	Australia	Australia	100	100
ETXSA Properties Pty Ltd	Australia	Australia	100	100

NOTE 20 – RELATED PARTIES

The consolidated financial statements include the financial statements of entX Limited and its wholly owned subsidiaries detailed in Note 19. entX Limited is the ultimate parent of the Group.

Transactions with Key Management Personnel

During the half year ended 30 June 2025, key management personnel including non-executive directors received compensation in the form of short-term employee benefits and post-employment benefits as part of their respective employment arrangements with the Company.

NOTE 20 – RELATED PARTIES……continued

Transactions with other related parties

The following table provides the aggregate income recognised during the reporting period relating to related parties as follows:

	Note	6 months to 30 June 2025 $	6 months to 30 June 2024 $
Related parties:			
UFP Investments LLC	(i)	-	-
Urtek LLC	(ii)	27,000	24,000
Australian Rare Earths Ltd	(iii)	-	10,975

(i) The Group has a 28.66% (2024: 28.66%) legal and beneficial interest in UFP Investments LLC and is accordingly an associate – see Note 9. During the reporting period, the Group provided a capital contribution of US$17,970 (2024: US$21,641) in accordance with PhosEnergy Inc.'s % ownership share of Investments LLC. There were no further transactions with UFP Investments LLC during the reporting period.

(ii) The Group has a 25.79% (2024: 25.79%) beneficial interest in Urtek LLC and is accordingly an associate– see Note 9. The Company provided management services to Urtek LLC during the reporting period. Amounts were billed at an amount agreed between the Company and Cameco Corporation and are due and payable under normal payment terms. No amounts were outstanding as at 30 June 2025 (31 December 2024: $Nil).

(iii) The Group has an arm's length equivalent agreement with Australian Rare Earths Limited ("AR3") whereby AR3 shares office space with the Group. Mr Bryn Jones was a director of both AR3 and entX, prior to resigning as a director of AR3 on 21 June 2024.

Terms and conditions of transactions with related parties

Other than where stated, services provided by related parties are made on arm's length basis both at normal market prices and on normal commercial terms.

NOTE 21 – CASH FLOW INFORMATION

Reconciliation of loss to net cash used in operating activities.

	6 months to 30 June 2025 $	6 months to 30 June 2024 $
Loss for the reporting period	**(2,788,634)**	**(1,698,224)**
Share based payments	259,334	-
Share based payments – forfeited options	-	(217,438)
Amortisation of intangible assets	8,704	18,295
Depreciation of property, plant and equipment	60,323	18,363
Amortisation – right-of-use asset	185,432	120,901
Finance costs - lease interest	37,020	6,771
Loss on sale of property plant & equipment – Elliston Property	28,439	-
Foreign exchange loss / (gain)	1,229	(3,497)
Operating loss before changes in working capital	(2,208,153)	(1,754,829)
(Increase)/decrease in assets:		
Trade and other receivables	288,820	(790,408)
Increase/(decrease) in liabilities:		
Trade and other payables	2,093,408	1,849,446
Provision for annual leave, long-service leave/bonus	(625,927)	(60,887)
Net cash used in operating activities	**(451,852)**	**(756,678)**

NOTE 22 – CONTRACT ASSETS AND CONTRACT LIABILITIES

GenX – CRCP Grant ($2.4M)

During 2022 the Group was awarded a $2,427,689 cash funding grant from the Commonwealth Department of Industry, Science, Energy and Resources (Commonwealth) as part of a Cooperative Research Centres Projects (CRCP) grant for development of the Group's GenX Betavoltaic Battery Pilot Manufacturing Process technology (the "CRCP Grant"). The CRCP Grant commenced in May 2022 and concluded in April 2025. As part of the CRCP Grant, the Group worked collaboratively with three research institutions and two industry partners and together contributed $3,597,067 (net of grant funds) over the life of the project, including in-kind contributions.

As at 30 June 2025, the Group has received $2,306,305 of the grant funding, including $374,859 during the half-year ended 30 June 2025. An amount of $302,571 has been recognised as other income in the reporting period, of which $121,384 remains recorded as a contract asset pending receipt of the final grant payment. The final instalment is expected in August 2025, following completion of end-of-project reporting obligations.

IsoMedica – CRCP Grant ($2.9M)

In November 2024, the Group was awarded a $2,915,000 cash funding grant from the Commonwealth Department of Industry, Science and Resources (Commonwealth) as part of the Cooperative Research Centres Projects (CRCP) Round 16 program (the "IsoMedica CRCP Grant"), which commenced in April 2025 and is expected to conclude by March 2028.

The IsoMedica CRCP Grant supports entX's Mines to Medicines project, which seeks to build a sovereign supply chain for lead-212 (Pb-212), a key isotope in Targeted Alpha Therapy (TAT) for treatment of advanced cancers such as prostate and neuroendocrine tumours. The project involves extracting precursor isotopes from industrial waste streams, leveraging the Group's novel processing technologies. This project reinforces entX's leadership in nuclear medicine and strengthens Australia's sovereign isotope production capabilities.

Grant funding is received in quarterly instalments in advance of expenditure, with the Group and its partners committed to contribute $3,901,406 (including $623,952 of in-kind support) over the project's duration.

During the half-year ended 30 June 2025, the Group received the first grant payment of $953,000, of which $111,376 was recognised in Profit or Loss as Other income and $841,624 recognised as a contract liability in the Statement of Financial Position.

Economic Recovery Fund (ERF) Grant Award ($1.9M)

In January 2025, the Company was awarded a $1,900,000 cash funding grant by the South Australian Government under the Economic Recovery Fund (ERF), to support the establishment of an innovative Isotope Manufacturing Facility in South Australia (the "ERF Grant"). This Facility will enable the extraction and processing of precursors to medical isotopes, including Lutetium-177 and Lead-212, for supply to the healthcare industry. The grant covers up to 50% of eligible project expenditures. The project is expected to be completed by 30 September 2026. This investment strengthens the Company's position in the nuclear medicine sector and supports the development of sovereign capabilities in isotope production.

As at 30 June 2025, no funding had been received; however, $43,034 was recognised under both Trade and Other Receivables and Contract Liabilities following submission of the Milestone 1 claim. In accordance with AASB 120 Accounting for Government Grants and Disclosure of Government Assistance, the deferred income method has been applied, with grant proceeds initially recognised as a liability and to be systematically recognised in profit or loss over the useful life of the facility once completed.

Australian Space Agency (ASA) Grant Award ($1M)

In January 2025, the Company was awarded a $1,000,000 grant by the Commonwealth of Australia under the Australian Space Agency's Moon to Mars Initiative: Supply Chain Capability Improvement Grants (the "ASA Grant").

The ASA Grant supports the Group's Pioneering Lunar Night Solutions: US Flight Heritage for an Australian RHU, aimed at developing and demonstrating the Company's novel Radioisotope Heating Unit (RHU) for lunar exploration. Grant funding will be allocated towards mission planning, regulatory approvals, supply chain development, and the establishment of flight heritage for the RHU. The project, which commenced in February 2025 and is targeted for completion by 30 November 2026, reinforces the Company's position in the international space industry.

During the reporting period, the Group received the full $1,000,000 of ASA Grant funding, of which $88,060 was recognised in profit or loss as Other income and $911,840 was recognised in the Statement of Financial Position as a Contract liability.

NOTE 22 – CONTRACT ASSETS AND CONTRACT LIABILITIES.....continued

SA Space Collaboration and Innovation Fund (SCIF) Grant Award ($0.2M)

In April 2025, the Group was awarded a $200,296 grant from the South Australian Government's Space Collaboration and Innovation Fund to support its "Innovative RHU Integration Solutions for Surviving the Lunar Night" project. The project is being undertaken in collaboration with ispace Inc., a leading Japanese space technology company and lunar exploration partner.

The grant will support engineering feasibility studies and integration work to develop Concept of Operations ("CONOPS") for entX's RHU, aimed at understanding the requirements for lunar night survival on international lunar lander and rover platforms. Through its partnership with ispace, the Group aims to conduct joint design reviews, define integration requirements, simulate mission scenarios, and develop proof-of-concept designs for RHUs, targeting long-duration survival in extreme lunar environments.

The project commenced in April 2025 and is scheduled for completion by January 2026, with the Group committing to contributing $200,296 (net of grant funds) over the life of the project.

During the reporting period, the Group received $180,266 in cash proceeds, of which $15,992 was recognised in profit or loss as Other income, with the balance of $164,274 recorded as a contract liability in the Statement of Financial Position.

NOTE 23 – COMMITMENTS AND CONTINGENCIES

There are no further commitments and contingencies as at 30 June 2025.

NOTE 24 – EVENTS SUBSEQUENT TO REPORTING DATE

The following events have occurred since the reporting date:

Issue of Placement Shares

- On 10 July 2025, the Company issued a further 666,667 new Shares pursuant to the Placement to sophisticated and professional investors, that was undertaken during the reporting period, raising a further $200,000 (before costs). Placement Shares were issued at $0.30 per Share.

- On 14 August 2025, the Company issued a further 10,500,000 new Shares pursuant to the Placement to sophisticated and professional investors, that was undertaken during the reporting period, raising a further $3,150,000 (before costs). Placement Shares were issued at $0.30 per Share.

There were no further significant events arising after the reporting date.

Directors' Declaration

The Directors of the Company declare that:

1. The Financial Statements and Notes, as set out on pages 9 to 25 are in accordance with the *Corporations Act 2001*, including:

   a) complying with Accounting Standard AASB 134 Interim Financial Reporting, and

   b) giving a true and fair view of the consolidated entity's financial position as at 30 June 2025 and of its performance for the half-year ended on that date.

2. In the Director's opinion there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Bryn Jones

Managing Director

Dated this 28th day of August 2025

Independent Auditor's Review Report

Grant Thornton Audit Pty Ltd
Grant Thornton House
Level 3
170 Frome Street
Adelaide SA 5000
GPO Box 1270
Adelaide SA 5001

T +61 8 8372 6666

Independent Auditor's Review Report

To the Members of entX Limited

Report on the half-year financial report

Conclusion

We have reviewed the accompanying half-year financial report of entX Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2025, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half year ended on that date, including material accounting policy information, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of entX Limited does not comply with the *Corporations Act 2001* including:

a giving a true and fair view of the Group's financial position as at 30 June 2025 and of its performance for the half year ended on that date; and

b complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES *110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Directors' responsibility for the half-year financial report

The Directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 30 June 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants

J L Humphrey
Partner – Audit & Assurance

Adelaide, 28 August 2025

Corporate directory

ABN: 31 164 573 728

Directors

Anthony Kiernan AM (Non-Executive Chairman)

Bryn Jones (Managing Director)

Tim Goyder (Non-Executive Director)

Tim Wise (Non-Executive Director)

Lucy Gauvin (Non-Executive Director)

Company Secretary

Damien Connor

Registered Office

Level 10, 111 Gawler Place

Adelaide, South Australia, 5000

Telephone: +61 (0)8 8470 1700

Email:

Share Registry

Computershare Investor Services Pty Ltd

Level 5, 115 Grenfell Street

ADELAIDE SA 5000

Auditors

Grant Thornton Audit Pty Ltd

Level 3, 170 Frome Street

ADELAIDE SA 5000

Stay in touch

Latest news, reports and presentations via email

Shareholders are encouraged to take advantage of the benefits of electronic communications by electing to receive communication from the Company and its share registry electronically.

Shareholders can change their communication preferences through the registry website: www.investorcentre.com

For more information about entX's activities, and to subscribe to receive the latest news, reports and presentations, please visit our website:

Website:

https://www.entx.com.au/

Subscribe to our News Alerts:

https://www.entx.com.au/
(Fill in your details in the 'Join our Newsletter' section at the bottom of the entX website)

X (formerly Twitter):

https://twitter.com/entX_Limited

LinkedIN:

https://www.linkedin.com/company/entxlimited/

YouTube:

https://www.youtube.com/channel/UCq7kHnzw0qt94empSCf5e7w

Instagram:

https://www.instagram.com/entx_limited/